Related Experiment Videos
Alzheimer disease therapeutics: perspectives from the developing world
1Department of Neurology, Aga Khan University Medical College, Karachi, Pakistan. saad.shafqat@aku.edu
Journal of Alzheimer'S Disease : JAD
|October 28, 2008
Summary
Dementia is a growing public health issue in developing nations, often dismissed as normal aging. Addressing this requires improved health infrastructure, education, and treatments for dementia care.
Area of Science:
- Public Health
- Gerontology
- Neurology
Background:
- Dementia is a significant health burden in low- and middle-income countries.
- Dementia is often culturally trivialized as a natural part of aging.
- Limited economic resources hinder elder care and healthcare systems in developing nations.
Purpose of the Study:
- To highlight the under-recognized public health challenge of dementia in the developing world.
- To identify barriers to effective dementia management in resource-limited settings.
- To propose necessary interventions for addressing the escalating dementia crisis.
Main Methods:
- Literature review on dementia prevalence and management in developing countries.
- Analysis of socio-cultural and economic factors impacting dementia care.
- Synthesis of expert opinions on anti-dementia drug efficacy.
Main Results:
- Dementia prevalence is high in developing countries, yet awareness and care are lacking.
- Cultural beliefs and economic constraints impede dementia recognition and management.
- Lack of expert consensus on drug efficacy complicates evidence-based practice.
Conclusions:
- Public health education is crucial to combat the trivialization of dementia.
- Development of health infrastructure is essential for adequate dementia care.
- Therapeutic advancements and clear treatment guidelines are needed to tackle the dementia crisis.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...